Radiometals are the mainstay of both diagnostic and therapeutic nuclear medicine because the choice of radionuclide is primarily dictated by nuclear decay characteristics rather than chemistry. 99mTC is the most frequently used diagnostic radionuclide and requires coordination in a diversity of chemical disguises to permit imaging of a variety of tissues and disease states. Therapeutic nuclear medicine is less advanced but can provide significant benefits provided the radionuclide is accurately targetted.
Introduction
Radiopharmaceuticals are radioactive drugs which can have either diagnostic or therapeutic applications. In diagnostic nuclear medicine, the radionuclide is used as a tracer to provide functional information about the tissue under investigation. The very short-lived positron-emitting radionuc|ides such as IC, 3N, 150 and are used for diagnosis in hospitals with access to highly specialised and expensive positron emission tomography (PET) facilities. However, most hospital nuclear medicine departments are not equipped for such work and need to use radionuclides suitable for single photon emission tomography (SPET). The nuclear properties required for such radionuclides are: 1. A half-life long enough both to make it readily available in the hospital and to allow it to be distributed in vivo according to the physiological function being investigated, but not so long as to give the patient more radiation dose than is justified by the requirements of the study. These needs frequently dictate a half-life of2-3 days. 2. A decay which gives rise to penetrating y-emissions to allow the distribution of the radionuclide to be measured, but is not accompanied by damaging, non-penetrating particulate radiations such as c-or particles.
In contrast, therapeutic radionuclides should have particulate radiations with an in vivo range sufficient to destroy the target tissue but not so long as to cause collateral damage and have little or no accompanying ,-emissions which could cause unnecessary radiation exposure to both the patient and hospital staff. Again, the half-life needs to be sufficiently long to allow availability to the hospital and in vivo distribution but is otherwise dictated by whether the radiation dose is to be delivered at a high dose rate over a short time or at a lower dose rate over an extended period. Figure 4 shows SPET images of a trauma patient 2 weeks after injury and following recovery. The scans give detailed information about the progression of brain function. The imaging of hypoxic (under-oxygenated)tissue is of potential importance because it may allow the identification and management of tumours resistant to radiotherapy or of at risk myocardium (hea muscle) in heart patients. A possible targeting mechanism is the intracellular reduction of nitroimidazoles ( Figure 5 ). The in vivo reduction of nitroimidazoles is mediated by cytosolic or mitochondrial enzymes but, in normoxic (normally oxygenated)cells, the first step is reversed due to reaction with oxygen (the "futile cycle"). In hypoxic cells, this reversal does not take place and products which may be unable to diffuse out of the cell occur.
The first 99mTC agent to employ this trapping mechanism was BMS-181321 ( Figure 6 ). Inspection of Figure 2 shows this is formed from a nitroimidazole derivative of PnAO. (-2.15 MBq/kg), the three-month post treatment levels had dropped-30% for platelets and -20% for leukocytes. This was adopted as the standard dose to allow for patient variation, whilst ensuring side-effects were kept below unacceptable levels. A double-blind study was conducted to compare patient response to 
Conclusions
Radiometals are the mainstay of both diagnostic and therapeutic nuclear medicine because the choice of radionuclide is primarily dictated by nuclear decay characteristics rather than chemistry. Although some metals are usefully targeted as simple salts, most uses require the application of carefully researched coordination chemistry to ensure delivery of the radionuclide to the target tissue.
